

Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



FDA ADVISORY No. - 2022-1620

0 1 517 2022

TO

ALL HEALTHCARE PROFESSIONALS AND THE

GENERAL PUBLIC

SUBJECT

Public Health Warning Against the Purchase and Use of the

Counterfeit Drug Product "Sero-Tet Tetanus Immune

Globulin Human 250 IU/mL"

The Food and Drug Administration (FDA) advises the public against the purchase and use of the counterfeit version of the following product:

AUTHENTIC





COUNTERFEIT





Counterfeit – The lot number and labeling requirements are not comparable with the standard features of the registered product.

Figure 1. Comparison between the Authentic and Verified Counterfeit Sero-Tet Tetanus Immune Globulin Human 250 IU/mL (Lot No. 080T18003)



All healthcare professionals and the general public are hereby warned as to the availability of this counterfeit drug product in the market which pose potential danger or injury to consumers. Consumers are also reminded to purchase drug product only from FDA-licensed establishments.

Likewise, all establishments and outlets are hereby warned against selling and/or dispensing of the said counterfeit product with the abovementioned features. The importation, selling or offering for sale of such is in direct violation of Republic Act No. 9711 or the Food and Drug Administration Act of 2009, and Republic Act No. 8203 or the Special Law on Counterfeit Drugs. Anyone found selling the said counterfeit drug product will be penalized.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at info@fda.gov.ph. To report continuous sale or distribution of unregistered health products, kindly e-mail us via ereport@fda.gov.ph, or through the online reporting facility, eReport, at www.fda.gov.ph/ereport. You may also call the Center for Drug Regulation and Research at telephone number (02) 8809-5596. For any suspected drug reaction (ADR), report immediately to FDA through this link: https://primarvreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH and fill out all the required fields.

Dissemination of the information to all concerned is requested.

DR. SAMUEL Director Gener

20220808114047